Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/8308
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Ketanserin for the treatment of preeclampsia
Author: Bolte, A.
van Eyck, J.
Gaffar, S.
van Geijn, H.
Dekker, G.
Citation: Journal of Perinatal Medicine, 2001; 29(1):14-22
Publisher: Walter de Gruyter & Co
Issue Date: 2001
ISSN: 0300-5577
1619-3997
Statement of
Responsibility: 
Antoinette C. Bolte, Jim van Eyck, Sharda F. Gaffar, Herman P. van Geijn, Gustaaf A. Dekker
Abstract: Objective: To compare maternal and perinatal outcome with the use of either intravenous ketanserin or dihydralazine in treatment of women with preeclampsia. Methods: The records from January 1989 to January 1997 of all patients receiving intravenous ketanserin or dihydralazine as first line antihypertensive therapy were reviewed and standardized data forms were completed. 315 charts of patients were identified and evaluated for effects on blood pressure, laboratory parameters, maternal and perinatal outcome. Results: During the study interval 169 patients received ketanserin and 146 dihydralazine. Significantly fewer antepartum (27% versus 38%, p = 0.04) and postpartum (25% versus 39%, p = 0.01) maternal complications were noted in patients receiving ketanserin. Occurrence of HELLP syndrome was significantly lower among patients who received ketanserin (20%) than among those who received dihydralazine (40%, p = 0.0001). Side-effects were reported with significantly higher frequency in patients receiving dihydralazine (60%) as compared to those receiving ketanserin (17%, p < 0.0001). Perinatal outcome was comparable, however, umbilical cord arterial pH values (mean ± SD) were higher with ketanserin compared to dihydralazine ( 7.25 ± 0.07 vs 7.23 ± 0.09, p = 0.038). The incidence of placental abruption was higher in patients receiving dihydralazine (5.5%) versus those receiving ketanserin (0.6%, p = 0.014). Conclusion: Ketanserin appears to be a better option than dihydralazine for treatment of severe preeclampsia since fewer maternal complications and side-effects were observed in patients receiving ketanserin.
Keywords: Liver; Humans; Pulmonary Edema; HELLP Syndrome; Pre-Eclampsia; Hemolysis; Ketanserin; Dihydralazine; L-Lactate Dehydrogenase; Aspartate Aminotransferases; Antihypertensive Agents; Platelet Count; Delivery, Obstetric; Logistic Models; Gestational Age; Pregnancy; Netherlands; Female
Description: Copyright © Walter de Gruyter
RMID: 0020012234
DOI: 10.1515/JPM.2001.002
Published version: http://www.atypon-link.com/WDG/doi/abs/10.1515/JPM.2001.002?journalCode=jpme
Appears in Collections:Obstetrics and Gynaecology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.